Expectedly, treatment with the anti‐CD8 mAb restored tumor growth as compared to isotype‐matched control mAb treatment (Figure 1f), indicating a contribution of CD8+ T cells to impaired growth in CIRT+HCQ tumors. Here, CD8A is linked to neoplasm.